REGULATORY
Establishment of Relief System for Victims of Health Damage Due to Anticancer Drugs Should Be Put Off: MHLW Study Group
The Ministry of Health, Labor and Welfare’s (MHLW) Study Group on Compensation for Health Damage Caused by Anticancer Drugs (chairman: Professor Emeritus Akio Morishima at Nagoya University) approved on July 13 a draft report concluding that the establishment of a…
To read the full story
REGULATORY
- LDP Pharma Project Team to Compile Roadmap Proposals after Industry Hearings
April 17, 2026
- DPJ Leader to Urge Drug Price Hikes, “Freeze” on Off-Year Revisions
April 17, 2026
- War-Linked Supply Impact Cases Climb to 34 as Japan Steps Up Response
April 17, 2026
- Meiji Pharma Chair Prods Drug Price Hikes as War Drives Up Costs: Diet
April 17, 2026
- Japan Eases Documentation Requirements for Excipients Listed in Foreign Pharmacopoeias
April 17, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





